Controversy continues with regard to antidepressants and withdrawal. Recent debates have focused on the prevalence and length of withdrawal, and some continue to state that withdrawal from these compounds constitutes ‘addiction’. In this editorial we examine the evidence underlying these recent debates. We acknowledge gaps in knowledge, and make suggestions for how the field can progress.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). 5th ed.Arlington, VA: American Psychiatric Publishing, Inc.
2.
BaldwinDSHuusomAKTMaehlumE (2006) Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study. Br J Psychiatry189: 264–272.
3.
BaldwinDSMontgomerySANilRet al. (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol10: 73–84.
4.
BethlehemJ (2010) Selection bias in web surveys. Int Stat Rev78: 161–188.
5.
CookCHeathFThompsonRL (2000) A meta-analysis of response rates in web- or internet-based surveys. Educ Psychol Meas60: 821–836.
6.
DaviesJReadJ (2018) A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?Addict Behav. Epub ahead of print 4 September 2018. DOI: 10.1016/j.addbeh.2018.08.027.
7.
GrootPCvan OsJ (2018) Antidepressant tapering strips to help people come off medication more safely. Psychosis10: 142–145.
8.
HaddadP (1999) Do antidepressants have any potential to cause addiction?Journal of Psychopharmacology (Oxford, England)13(3): 300–307.
9.
JauharSHayesJ (2019) The war on antidepressants: What we can, and can’t conclude, from the systematic review of antidepressant withdrawal effects by Davies and Read. Addict Behav. Epub ahead of print 23 January 2019. DOI: 10.1016/j.addbeh.2019.01.025.
10.
JhaMKRushAJTrivediMH (2018) When discontinuing SSRI antidepressants is a challenge: Management tips. Am J Psychiatry175: 1176–1184.
11.
JudgeRParryMGQuailDet al. (2002) Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol17(5): 217–225.
12.
LaderMStenderKBürgerVet al. (2004) Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depression and Anxiety19(4): 241–248.
13.
Le NouryJNardoJMHealyDet al. (2015) Restoring Study 329: Efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ351: h4320.
14.
LeshnerAI (1997) Addiction is a brain disease, and it matters. Science278: 45–47.
15.
MannAMMacphersonAS (1959) Clinical experience with imipramine (G22355) in the treatment of depression. Can Psychiatr Assoc J4: 38–47.
16.
MartinRMMayMGunnellD (2006) Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004. Br J Clin Pharmacol61: 224–228.
17.
MedawarC (1997) The Antidepressant web: Marketing depression and making medicines work. The Int J Risk Saf Med10: 75–126.
MontgomerySAKennedySHBurrowsGDet al. (2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol19: 271–280.
20.
MurphySMTyrerP (1991) A double-blind comparison of the effects of gradual withdrawal of lorazepam, diazepam and bromazepam in benzodiazepine dependence. Br J Psychiatry158: 511–516.
21.
NevelsRMGontkovskySTWilliamsBE (2016) Paroxetine-the antidepressant from hell? Probably not, but caution required. Psychopharmacol Bull46: 77–104.
22.
NielsenMHansenEHGøtzschePC (2012) What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addiction107: 900–908.
23.
NuttDJ (2003) Death and dependence: Current controversies over the selective serotonin reuptake inhibitors. J Psychopharmacol17: 355–364
24.
OehrbergSChristiansenPEBehnkeKet al. (1995) Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry167: 374–379.
25.
PriceJSWallerPCWoodSMet al. (1996) A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol42: 757–763.
26.
RenoirT (2013) Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: A review of the clinical evidence and the possible mechanisms involved. Front Pharmacol4: 45.
RushAJTrivediMHWisniewskiSRet al. (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry163: 1905–1917.
29.
TonksA (2002) Withdrawal from paroxetine can be severe, warns FDA. BMJ324: 260.
WellerIVDAshbyDBrookRet al. (2005) Report of the CSM Expert Working Group on the safety of selective serotonin reuptake inhibitors. London: Medicines and Healthcare Products Regulatory Agency.
32.
WilesNThomasLAbelAet al. (2013) Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet (London, England)381: 375–384.
33.
ZajeckaJFawcettJAmsterdamJet al. (1998) Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study. J Clin Psychopharmacol18: 193.
34.
ZoharJNuttDJKupferDJet al. (2014) A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol: The Journal of the European College of Neuropsychopharmacology24: 1005–1014.
